Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA

Neuropharmacology

Volumn 76, Issue PART A, 2014, Pages 156-168

  Dominguez Meijide, Antonio ^a,b   Villar Cheda, Begoña ^a,b   Garrido Gil, Pablo ^a,b   Sierrra Paredes, German ^a   Guerra, Maria J ^a,b   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Angiotensin; Candesartan; l DOPA; Neuroprotection; Parkinson; Serotonin

Indexed keywords

BENSERAZIDE; CANDESARTAN HEXETIL; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LEVODOPA; OXIDOPAMINE; SELEGILINE; SEROTONIN; SEROTONIN 1B RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DECARBOXYLATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TISSUE LEVEL; ENZYME RELEASE; LOCOMOTION; LOW DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ROTAROD TEST; SINGLE DRUG DOSE; STRIATE CORTEX;

3,4-DIHYDROXYPHENYLACETIC ACID; 5-HIAA; 5-HT; 6-HYDROXYDOPAMINE; 6-OHDA; AII; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN TYPE-1 RECEPTOR; ANGIOTENSIN TYPE-2 RECEPTOR; AREA UNDER THE CURVE; AT1; AT2; AUC; CANDESARTAN; DOPAC; HIGH PERFORMANCE LIQUID CHROMATOGRAPH; HOMOVANILLIC ACID; HPLC; HVA; L-3,4-DIHYDROXYPHENYLALANINE METHYL ESTER HYDROCHLORIDE; L-DOPA; METABOLITE 5-HYDROXYINDOLACETIC ACID; NEUROPROTECTION; ORP; OVERALL ROD PERFORMANCE; PARKINSON; RAS; RENIN-ANGIOTENSIN SYSTEM; SEM; SEROTONIN; STANDARD ERROR OF THE MEAN; TH; TYROSINE HYDROXYLASE; WB; WESTERN BLOT ANALYSIS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BENZIMIDAZOLES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; LEVODOPA; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, DOPAMINE; SEROTONIN; TETRAZOLES;

EID: 84886516759     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.07.016     Document Type: Article

References (55)

1. A. Anzalone, J.E. Lizardi-Ortiz, M. Ramos, C. De Mei, F.W. Hopf, C. Iaccarino, B. Halbout, J. Jacobsen, C. Kinoshita, M. Welter, M.G. Caron, A. Bonci, D. Sulzer, and E. Borrelli Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors J. Neurosci. 32 2012 9023 9034
2. D.W. Brodell, N.T. Stanford, C.E. Jacobson, P. Schmidt, and M.S. Okun Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design BMJ Open 2 6 2012
3. D.C. Brown, L.J. Steward, J. Ge, and N.M. Barnes Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo Br. J. Pharmacol. 118 1996 414 420 (Pubitemid 26149291)
4. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund Involvement of the serotonin system in l-dopa-induced dyskinesias Parkinsonism Relat. Disord. 14 Suppl. 2 2008 S154 S158
5. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias Prog. Brain Res. 172 2008 465 478
6. P. Cassis, S. Conti, G. Remuzzi, and A. Benigni Angiotensin receptors as determinants of life span Pflugers Arch. 459 2010 325 332
7. L.X. Cubeddu, and I.S. Hoffmann Operational characteristics of the inhibitory feedback mechanism for regulation of dopamine release via presynaptic receptors J. Pharmacol. Exp. Ther. 223 1982 497 501 (Pubitemid 12005754)
8. C. De Mei, M. Ramos, C. Iitaka, and E. Borrelli Getting specialized: presynaptic and postsynaptic dopamine D2 receptors Curr. Opin. Pharmacol. 9 2009 53 58
9. L.P. Dwoskin, A.L. Jewell, and L.A. Cassis DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum Naunyn Schmiedebergs Arch. Pharmacol. 345 1992 153 159
10. M.G. Fornaretto, C. Caccia, M.G. Caron, and R.G. Fariello Dopamine receptors status after unilateral nigral 6-OHDA lesion. Autoradiographic and in situ hybridization study in the rat brain Mol. Chem. Neuropathol. 19 1993 147 162 (Pubitemid 23183445)
11. J.J. Gildea Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance Curr. Opin. Nephrol. Hypertens. 18 2009 28 32
12. P. Gohlke, S. Von Kugelgen, T. Jurgensen, T. Kox, W. Rascher, J. Culman, and T. Unger Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats J. Hypertens. 20 2002 909 918 (Pubitemid 34913672)
13. T.N. Grammatopoulos, S.M. Jones, F.A. Ahmadi, B.R. Hoover, L.D. Snell, J. Skoch, V.V. Jhaveri, A.M. Poczobutt, J.A. Weyhenmeyer, and W.M. Zawada Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra Mol. Neurodegener. 2 2007 1
14. F. Hefti, E. Melamed, and R.J. Wurtman The site of dopamine formation in rat striatum after l-dopa administration J. Pharmacol. Exp. Ther. 217 1981 189 197 (Pubitemid 11103843)
15. M.T. Herrero, S.J. Augood, H. Asensi, E.C. Hirsch, Y. Agid, J.A. Obeso, and P.C. Emson Effects of l-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys Brain Res. Mol. Brain Res. 42 1996 149 155 (Pubitemid 26345420)
16. J.L. Hudson, C.G. Van Horne, I. Stromberg, S. Brock, J. Clayton, J. Masserano, B.J. Hoffer, and G.A. Gerhardt Correlation of apomorphine and amphetamine - induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats Brain Res. 626 1993 167 174 (Pubitemid 23306825)
17. T. Hussain, R. Abdul-Wahab, D.K. Kotak, and M.F. Lokhandwala Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules Hypertension 32 1998 1054 1059 (Pubitemid 29001436)
18. T.A. Jenkins Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats Neurosci. Lett. 444 2008 186 189
19. B. Joglar, J. Rodriguez-Pallares, A.I. Rodríguez-Perez, P. Rey, M.J. Guerra, and J.L. Labandeira-Garcia The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease J. Neurochem. 109 2009 656 669
20. P.G. Kehoe, and G.K. Wilcock Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol. 6 2007 373 378 (Pubitemid 46389616)
21. F. Khan, Z. Spicarová, S. Zelenin, U. Holtbäck, L. Scott, and A. Aperia Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells Am. J. Physiol. Renal. Physiol. 295 2008 F1110 F1116
22. J.L. Labandeira-Garcia, J. Rodriguez-Pallares, A.I. Rodríguez- Perez, P. Garrido-Gil, B. Villar-Cheda, R. Valenzuela, and M.J. Guerra Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease Am. J. Neurodegener. Dis. 1 2012 226 244
23. A. Lopez, A. Muñoz, M.J. Guerra, and J.L. Labandeira-Garcia Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum Neuroscience 103 2001 639 651 (Pubitemid 32239332)
24. A. Lopez-Real, J. Rodriguez-Pallares, M.J. Guerra, and J.L. Labandeira-Garcia Localization and functional significance of striatal neurons immunoreactive to aromatic l-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models Brain Res. 969 2003 135 146 (Pubitemid 36369621)
25. M. Lou, A. Blume, Y. Zhao, P. Gohlke, G. Deuschl, T. Herdegen, and J. Culman Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat J. Cereb. Blood Flow Metab. 24 2004 536 547 (Pubitemid 38608286)
26. C. Marchesi, P. Paradis, and E.L. Schiffrin Role of the renin-angiotensin system in vascular inflammation Trends Pharmacol. Sci. 29 2008 367 374
27. P.K. Mehta, and K.K. Griendling Angiotensin II cell signaling, physiological and pathological effects in the cardiovascular system Am. J. Physiol. Cell Physiol. 29 2007 C82 C97
28. F.A. Mendelsohn, T.A. Jenkins, and S.F. Berkovic Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats1993 Brain Res. 613 1993 221 229 (Pubitemid 23179972)
29. B. Mertens, M. Varcin, Y. Michotte, and S. Sarre The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death Eur. J. Neurosci. 34 2011 1141 1148
30. L.J. Min, M. Mogi, M. Iwai, and M. Horiuchi Signaling mechanisms of angiotensin II in regulating vascular senescence Ageing Res. Rev. 8 2009 113 121
31. M. Mogi, and M. Horiuchi Effects of angiotensin II receptor blockers on dementia Hypertens. Res. 32 2009 738 740
32. A. Muñoz, Q. Li, F. Gardoni, E. Marcello, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Björklund, E. Bezard, and M. Carta Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia Brain 131 2008 3380 3394
33. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdère Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiol. Dis. 41 2011 585 590
34. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Press New York
35. M.I. Phillips, and E.M. de Oliveira Brain renin angiotensin in disease J. Mol. Med. 86 2008 715 722
36. M. Platten, S. Youssef, E.M. Hur, P.P. Ho, M.H. Han, T.V. Lanz, L.K. Phillips, M.J. Goldstein, R. Bhat, C.S. Raine, R.A. Sobel, and L. Steinman Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity Proc. Natl. Acad. Sci. U. S. A. 106 2009 14948 14953
37. R.N. Re Tissue renin angiotensin systems Med. Clin. North Am. 88 2004 19 38 (Pubitemid 38160940)
38. P. Rey, A. Lopez-Real, S. Sanchez-Iglesias, A. Muñoz, R. Soto-Otero, and J.L. Labandeira-Garcia Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons Neurobiol. Aging 28 2007 555 567 (Pubitemid 46282209)
39. J. Rodriguez-Pallares, P. Rey, J.A. Parga, A. Muñoz, M.J. Guerra, and J.L. Labandeira-Garcia Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS Neurobiol. Dis. 31 2008 58 73
40. A.I. Rodriguez-Perez, A. Dominguez-Meijide, J.L. Lanciego, M.J. Guerra, and J.L. Labandeira-Garcia Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage Age (Dordr.) 2013 Epub 2012 Sep 18 (ahead of print)
41. A.I. Rodriguez-Perez, R. Valenzuela, B. Villar-Cheda, M.J. Guerra, and J.L. Labandeira-Garcia Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system Brain 135 2012 124 138
42. G. Rozas, M.J. Guerra, and J.L. Labandeira-García An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism Brain Res. Brain Res. Protoc. 2 1997 75 84 (Pubitemid 28277496)
43. G. Rozas, and J.L. Labandeira García Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test Brain Res. 749 1997 188 199 (Pubitemid 27104199)
44. G. Rozas, E. López-Martín, M.J. Guerra, and J.L. Labandeira-García The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism J. Neurosci. Methods 83 1998 165 175 (Pubitemid 28442608)
45. G.R. Sarma, V. Kamath, T. Mathew, and A.K. Roy A case of parkinsonism worsened by losartan: a probable new adverse effect Mov. Disord. 23 2008 1055
46. T. Schallert, D.A. Kozlowski, J.L. Humm, and R.R. Cocke Use-dependent structural events in recovery of function Adv. Neurol. 73 1997 229 238
47. J. Stegbauer, D.H. Lee, S. Seubert, G. Ellrichmann, A. Manzel, H. Kvakan, D.N. Muller, S. Gaupp, L.C. Rump, R. Gold, and R.A. Linker Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system Proc. Natl. Acad. Sci. U. S. A. 106 2009 14942 14947
48. R.D. Todd, J. Carl, S. Harmon, K.L. O'Malley, and J.S. Perlmutter Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons J. Neurosci. 16 1996 7776 7782 (Pubitemid 26389716)
49. 1-receptor blocker Eur. Heart J. (Supplement H) 2004 H11 H16
50. S. Villapol, A.K. Yaszemski, T.T. Logan, E. Sánchez-Lemus, J.M. Saavedra, and A.J. Symes Candesartan, an angiotensin AT1-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice Neuropsychopharmacology 37 2012 2817 2829
51. B. Villar-Cheda, J. Rodríguez-Pallares, A. Muñoz, R. Valenzuela, M.J. Guerra, O.C. Baltatu, and J.L. Labandeira-Garcia Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease Eur. J. Neurosci. 32 2010 1695 1706
52. B. Villar-Cheda, R. Valenzuela, A.I. Rodriguez-Perez, M.J. Guerra, and J.L. Labandeira-Garcia Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration Neurobiol. Aging 33 2012 204.e1-11
53. J.W. Wright, and J.W. Harding The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases Pflugers Arch. 465 2013 133 151
54. C. Zeng, Y. Liu, Z. Wang, D. He, L. Huang, P. Yu, S. Zheng, J.E. Jones, L.D. Asico, U. Hopfer, G.M. Eisner, R.A. Felder, and P.A. Jose Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells Circ. Res. 99 2006 494 500 (Pubitemid 44337821)
55. C. Zeng, Y. Luo, L.D. Asico, U. Hopfer, G.M. Eisner, R.A. Felder, and P.A. Jose Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats Hypertension 42 2003 787 792 (Pubitemid 37237326)